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Oral Presentations S169CD127 expression on CD8 +T cells, consistent with their rapid
clonal expansion and differentiation. Multiplexed Luminex cytokine
analysis demonstrated high-level secretion of IL-18 and IL-1RA,
with no increased secretion of TNF, IL-1b or IL-17 despite severe
GvHD.
The four treated recipients demonstrated rapid donor engraft-
ment, but, unlike the controls, they were significantly protected
against clinical and immunologic GvHD: They displayed neither
the skin rash nor the profuse diarrhea noted in the control animals,
and flow cytometric analysis demonstrated control of T cell prolifer-
ation, maintenance of CD127 expression levels, and inhibition of
IL-18 and IL-1RA cytokine secretion.
Conclusions:We have established a robust model of MHC haploi-
dentical HSCT andGvHDusing anMHC-defined Rhesus macaque
colony.We find that unprotected primate GvHD is characterized by
rapid T cell proliferation, with concomitant loss of expression of
CD127 on CD8 +T cells. In addition, it is associated with high level
secretion of IL-18 and IL-1RA. Finally, we find that CD28/CD40-
directed costimulation blockade in combination with sirolimus can
effectively inhibit the clinical, cellular and serum hallmarks of
GvHD during primate haploidentical BMT. This approach thus
may deserve close scrutiny as a possible clinical strategy for GvHD
prevention.
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FEASIBILITY, SAFETY, EFFICACY AND IMMUNOLOGIC IMPACT OF DAILY
ULTRA-LOW-DOSE INTERLEUKIN-2 FOR STEROID-REFRACTORY
CHRONIC GRAFT-VERSUS-HOST DISEASE: A PHASE I STUDY
Koreth, J.1, Stevenson, K.E.2, Kim, H.T.2, McDonough, S.1, Ho, V.T.1,
Alyea, E.P.1, Cutler, C.1, Armand, P.1, Antin, J.H.1, Ritz, J.1,
Soiffer, R.J.1 1Dana-Farber Cancer Institute, Boston, MA; 2Dana-
Farber Cancer Institute, Boston, MA
RegulatoryTcells (Treg) are deficient in chronic graft-versus-host-
disease (cGVHD). Interleukin-2 (IL-2) is critical in Treg develop-
ment, expansion and activity. We hypothesized daily subcutaneous
(SC) ultra-low-dose IL-2 (8 weeks on, 4 weeks off) may expandTregs
in steroid-refractory cGVHD. We report phase-I IL-2 outcomes at
dose-levels:A) 0.310^6 IU/m2 andB)110^6 IU/m2.Dose-level-C
accrual is ongoing. Concurrent immunosuppression was allowed.
11 patients accrued; 7 and 4 at dose-levels-A and -B. Median age
was 44 years (30-57). Median time from HSCT and cGVHD was
1021 (420-4714) and 784 (117-2233) days. cGVHD sites were skin
(11pts),mouth (6pts), eyes (4 pts), liver (3 pts), lung (2 pts), esophagus
(1 pt). Patients had amedian of 3 (range, 1-3) concurrent immunosup-
pressives: steroids (11 pts), sirolimus (5 pts), MMF (5 pts), tacrolimus
(4 pts). Discontinued prior therapies were rituximab (6 pts), ECP
(4 pts), MMF (2 pts), sirolimus (2 pts), cyclosporine (1 pt), thalido-
mide (1 pt), denileukin-diftitox (1 pt), alemtuzumab (1 pt).
No dose-limiting toxicity (DLT) GVHD flare occurred. One pa-
tient (lvl-A) had CTC grade-4 hemolytic-uremic-syndrome after
Hemophilus-B bacteremia at 5 weeks of IL-2 (and prednisone, tacro-
limus, sirolimus), reported as a DLT. No other DLT occurred. An-
other patient (lvl-A) hadCTCgrade-4MRSApneumonia at 8 weeks,
unrelated to IL-2 (on prednisone, sirolimus, MMF; also had MRSA
pneumonia pre-IL-2). No other significant infection was docu-
mented. One patient (lvl-B) discontinued IL-2 at 4 days for CTC
grade-1 fatigue.
Of 9 evaluable patients, 5 had a partial response, 1 had a mixed re-
sponse, and 3 had stable disease. Responses were scored in skin and
liver (mouth, eye received topical therapy). 4 of 5 responders chose
extended IL-2 (range, 1.5-15 months) given clinical benefit. The
5th, with resolving liver cGVHD, had IL-2 withheld for MRSA
pneumonia. He died of progressive liver cGVHD off IL-2.
IL-2 induced a 3-5-fold increase in CD4 +CD25 + CD127- Tregs
(Table). At 1, 2, 4, 6 and 8 weeks, IL-2 increased Treg significantly
over baseline (median difference5 17, 36, 60, 62, 59; p5 0.03, 0.04,
0.06, 0.05, 0.03, respectively). Similar changes were not seen in NK,
NK-T, or conventional T-cells.
We identify feasibility, safety, and efficacy of IL-2 in refractory
cGVHD. Treg expansion was marked despite steroid and calci-
neurin-inhibitor use. Ultra-low-dose SC IL-2 is a promising strategy
for cGVHD therapy and in-vivo Treg expansion.Table. Summary Statistics for CD41CD251CD127- T-reg-
ulatory Cells: Absolute Counts
Week N Median (range) cells/mLTreg Pre 9 17.3 (1.7, 41.8)
1 8 26.3 (14.3, 97.5)
2 10 50.2 (5.7, 400.9)
4 7 87.5 (22.2, 227.0)
6 9 67.7 (7.4, 188.5)
8 7 52.5 (22.3, 235.6)12 7 32.2 (10.6, 47.3)On IL-2: Week 1-8; Off IL-2: Week 8-12.40
ALLOGENEIC HUMAN MESENCHYMAL STEM CELL THERAPY (PROCHY-
MAL) AS A RESCUE AGENT FOR SEVERE TREATMENT RESISTANT
GVHD IN PEDIATRIC PATIENTS
Kurtzberg, J.1, Prasad, V.1, Grimley,M.S.2, Horn, B.3, Carpenter, P.A.4,
Jacobsohn, D.5, Prockop, S.6 1Duke University Medical Center, Durham,
NC; 2Methodist Healthcare System, SanAntonio, TX; 3University of Cal-
ifornia, San Francisco, CA; 4FredHutchinson Cancer Research Center, Se-
attle, WA; 5Childrens Memorial Hospital, Chicago, IL; 6Memorial
Sloan-Kettering Cancer Center, New York, NY
Severe acute graft vs. host disease (GVHD) unresponsive to ste-
roid and other immunosuppressive therapy typically leads to poor
outcomes and high mortality. Case reports of human mesenchymal
stem cells (MSCs) used for the rescue of pediatric patients with
severe GVHD resistant to multiple second line agents has generated
interest in the therapy because of its potential efficacy and encourag-
ing safety profile. In this study we evaluate the risk/benefit profile of
MSCs (Prochymal) administered under an FDA Expanded Access
Program (Protocol 275) as a rescue agent for treatment resistant
GVHD in pediatric patients.
Methods: Children with Grade B-D aGVHD failing steroids and
other agents were eligible for enrollment. Patients were given 8 bi-
weekly infusions of 2  106 cells/kg for 4 weeks, with an additional
4 infusions weekly after day 28 in patients with a partial response, de-
fined as improvement in at least one organ without progression in
others.
Results: 59 patients (median age of 8 years, 61% male, 55% Cauca-
sian, 83% recipient of an unrelated graft, and 41% cord blood) were
treated. At baseline, the distribution of aGVHD grades B:C:D was 6
(10%): 20 (33%): 33 (57%). Themedian duration of aGVHDbefore
enrollment was 29 days, and patients failed an average of 3.2 lines of
treatment for GVHD. Organ involvement was 60% skin, 87% gas-
trointestinal, and 38% liver. At day 28, overall response (OR), defined
as organ improvement of at least one stage without worsening in any
other,was 64%;17%of patients had stable disease ormixed response;
and 19% experienced progression. By grade, 28 day ORwas 67% for
B, 75% for C, and 58% for D. Response by organ was recorded, with
47% of skin, 23% of GI, and 39% of liver GVHD completely
responding (stage 0) within the first 28 days of treatment.Overall sur-
vival through study duration (day 100) was 62%. Achieving an OR at
day 28 resulted in a significantly higher probability of survival when
compared to patients who progressed within the first 28 days (76%
vs 9%, p\0.05). Prochymal was generally well tolerated and there
was no evidence of ectopic tissue formation.
Conclusion: Treatment with Prochymal produced a 64% response
rate in patients with otherwise refractory severe GVHD patients by
day 28. Response to Prochymal correlated with improved overall
survival at 100 days. MSC therapy appears to have an excellent
risk/benefit profile and should be considered in pediatric patients
with GVHD non-responsive to steroids.41
PROCHYMAL IMPROVES RESPONSE RATES IN PATIENTSWITH STEROID-
REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR-GVHD) INVOLV-
ING THE LIVER AND GUT: RESULTS OF A RANDOMIZED, PLACEBO-CON-
TROLLED, MULTICENTER PHASE III TRIAL IN GVHD
Martin, P.J.1, Uberti, J.P.2, Soiffer, R.J.3, Klingemann, H.4,
Waller, E.K.5, Daly, A.S.6, Herrmann, R.P.7, Kebriaei, P.8 1Fred
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Background and Methods: Steroid-refractory acute GVHD (SR-
GVHD) remains a significant complication of allogeneic hematopoi-
etic cell transplantation (HCT). Prochymal (Mesenchymal Stem
Cells, MSC, derived from unrelated volunteer adult donors) was
evaluated in addition to standard of care, including institutionally se-
lected second line treatment, in a randomized (2:1) trial in patients
with SR-GVHD (Protocol 280). Patients received 8 infusions of 2
 106 MSC/kg over 4 weeks (or volume equivalent for placebo),
with an additional 4 infusions administered weekly after day 28 in pa-
tients who had a partial response, defined as improvement in at least
one organ without progression in others. The primary endpoint was
durable complete response (DCR) for$ 28 days. Additional pro-
spectively defined outcomes included responses in patients by organ
involvement. P-values were based on Chi-square tests, unless other-
wise specified.
Patients and Results: 244 patients with SR-GVHD (skin involve-
ment n5 144, GI involvement n5 179, liver involvement n5 61)
were enrolled and treated on study: Prochymal (n5 163), placebo
(n5 81). There were no significant differences in age, pre-trans-
plant conditioning, graft source, HLA-matching or second-line
therapy between treatment arms. For the Prochymal and placebo
arms, respectively, the grades of GVHD at entry were B (22%
vs. 26%), C (51% vs. 58%), and D (27% vs. 16%). The respective
DCR rates were 35% vs. 30% (p5 0.3) in the ITT population and
40% vs. 28% (p5 0.08) in the per protocol population. Results for
secondary endpoints are shown in the table. Patients with GvHD
affecting all 3 organs had overall complete or partial responses
rate of 63% vs. 0% (n5 22, p\0.05, Fisher’s exact test) at day
28. Patients treated with Prochymal had less progression of liver
GVHD at weeks 2 and 4 respectively (32% vs 59%, p5 0.05;
and 37% vs. 65%, p5 0.05). The incidence of infections was not
different between arms. Incidence rates were 9% vs. 8% for recur-
rent malignancy, 1.8% vs. 2.5% for infusional toxicity, and 0.6%
vs. 4.6% for discontinuation due to an AE in Prochymal versus
Placebo, respectively.
Conclusion:GVHDwith liver or gut involvement is a life-threaten-
ing complication of HCT. Our results suggest that the addition of
Prochymal produced significant improvement without additive tox-
icity in patients with SR-GVHD involving visceral organs.
Overall Complete or Partial Response Rates in Patients
According to Organ Involvement
Day 100 Response RateOrgan Prochymal Placebo Odds Ratio 95% CI P ValueOverall 82% 73% 1.7 0.9-3.1 0.12
Skin 78% 77% 1.1 0.5-2.4 0.9
Liver 76% 47% 3.6 1.1-11.2 \0.05
Gut 82% 68% 2.2 1.1-4.4 \0.0542
CRUCIAL ROLE FOR CROSS-PRESENTATION IN THE INDUCTION OF GVHD
BY T CELLS DIRECTED AGAINST A SINGLE IMMUNODOMINANT MINOR
HISTOCOMPATIBILITY ANTIGEN DESPITE LACK OF EPITOPE SPREADING
Toubai, T.1, Tawara, I.1, Malter, C.1, Matzinger, P.2, Reddy, P.1 1Uni-
versity of Michigan, Ann Arbor, MI; 2NIAID, NIH, Bethesda, MD
The current paradigm indicates that epitope speading is critical
for GVHD after MHCmatched minor antigen (miHA) mismatched
BMT. Because clinical data suggest that sex mismatched antigens are
relevant miHAs for GVH responses, we directly tested relevance of
epitope spreading by inducingGVHDin the presence of only a single
immuno-dominant Y antigen disparity. We utilized female (F)/
male(M) MHC matched BMT with anti-H-Y monospecific,
H-2(b)-restricted T cell receptor transgenic (TCR Tg) MataHariCD8+ T cells. B6 [M and F] animals were lethally irradiated and
transplanted with TCD BM and 1106 splenic CD8+ T cells from
\MataHari donors. None of the syngeneic female B6 animals devel-
oped GVHD and all of them survived. By contrast, all of the alloge-
neic male animals that received MataHari T cells showed severe
clinical GVHD and died after BMT (P\0.0001, see Table).
GVHD specific death was confirmed by target organ (GI tract and
liver) histopathology on day +7 after BMT (P\0.005). To deter-
mine if the precursor frequency alloreactive donor T cells is critical,
we reduced the dose of the MataHari T cells by ten fold (1105) and
mixed them with syngeneic T cells (1:9 ratio) from male B6 donors.
Significant GVHD mortality was observed in the MataHari group
(33% vs. 0%, P\0.01) demonstrating that the presence of sufficient
precursor T cells against a single immuno-dominat miHA can
induce significant GVHD even in the absence of epitope spreading.
GVHD mortality was also observed when two other anti-H-Y spe-
cific TCR Tg CD4+ (Marilyn and Rachel) were utilized as donor
T cells ruling out any CD8+ T cell only or strain dependent artifacts.
Mechanistic studies were performed to determine whether direct
and/or cross-presentation (on host or donor hematopoietic derived
APCs) of the immunodominant miHA is critical for GVHD.
[F/M], [II-/-/M] and [M/ F] bone marrow chimeras gener-
ated, lethally re-irradiated and injected with TCD-BM and Marilyn
CD4+ T cells. The [F/M], [II-/-/M] animals (express HY anti-
gen on only non-hematopoietic target cells) died from severe
GVHD while the [M/ F] animals (express HY antigen on only
hematopoietic cells) showed only modest GVHD. Collectively our
data (see Table) demonstrate that (a) in contrast to the current
dogma, epitope spreading is not always required for GVHD (b)
the immunodominant antigen expression on target tissues is critical
and (c) this antigen can be efficiently cross-presented by either host
or donor APCs.
GVHD across single immuno-dominant Yantigen miHA
GVHD mortality
Donor T cells (all of B6\ TCDBM) Recipient * P\0.01MataHari (CD81 Tg, 1x106) B6 (female) 0%
MataHari (CD81 Tg, 1x106) B6 (male) 100%
MataHari (CD81 Tg, 0.1x106) B6 (male) 33%
Marilyn (CD41 Tg, 1x106) B6 (male) 100%
Rachel (CD41 Tg, 1x106) B6 (male) 100%
Marilyn (CD41 Tg, 1x106) [B6\ into B6_ 100%
Marilyn (CD41 Tg, 1x106) [B6(male) into B6\ 25%
Marilyn (CD41 Tg, 1x106) [II-/- into B6_ 100%43
PROSPECTIVE EVALUATION OF PROTEOMIC PATTERN SPECIFIC FOR
AGVHD IN MORE THAN 300 PATIENTS
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6University of Newcastle, Newcastle upon Tyne, United Kingdom; 7Med-
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Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is a curative treatment for many hematologic malignancies or hema-
topoietic dysfunction syndromes in adult patients, but the applica-
tion is still limited due to major complications, such as severe graft
versus host disease (GvHD) and/or infectious complications. Diag-
nosis of aGvHD is based on clinical features and biopsies, a non
invasive, unbiased laboratory test was developed earlier and has
been evaluated prospectively and blinded onmore than 1290 samples
collected from more than 327 patients undergoing allo-HSCT at
Hannover Medical School (MHH) and 7 additional clinics. The
majority of the patients included was transplanted for hematological
malignancies (n5 320), 9 for hematopoietic failure syndromes,
